(redirected from Bepreve)


(be-poe-tass-teen) ,


(trade name)


Therapeutic: ocular agents
Pharmacologic: antihistamines
Pregnancy Category: C


Treatment of itching associated with allergic conjunctivitis.


Acts as a histamine H1 receptor antagonist; also inhibits the release of histamine from mast cells; does not bind to or inactivate histamine.

Therapeutic effects

Decreased ocular itching associated with allergic conjunctivitis.


Absorption: Some systemic absorption follows ophthalmic administration.
Distribution: Unknown.
Metabolism and Excretion: Minimally metabolized by the liver; 75–90% excreted unchanged in urine.
Half-life: Uknown.

Time/action profile (antihistaminic activity)

ophthwithin 15 min1–2 hr†12 hr
†blood levels


Contraindicated in: Hypersensitivity.
Use Cautiously in: Contact lens use ; Obstetric: Use during pregnancy potential maternal benefit justifies the potential risk to fetus; Lactation: Use cautiously during breastfeeding; Pediatric: Safe and effective use in children <2 yr has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • nasopharyngitis


  • taste in mouth following instillation (most frequent)


Drug-Drug interaction

None noted.


Ophthalmic (Adults) One drop in affected eye(s) twice daily.


Ophthalmic solution: 1.5%

Nursing implications

Nursing assessment

  • Assess signs and symptoms of allergic conjunctivitis (redness, itching, watering) periodically during therapy.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Ophthalmic: Instill 1 drop into affected eyes twice daily. See for administration guidelines.

Patient/Family Teaching

  • Instruct patient to instill bepotastine drops as directed. Do not touch dropper to eye or to any surface.
  • Advise patient to remove contact lens prior to instillation. Do not use bepotastine for treatment of irritation related to contact lens. Do not wear contact lens if eyes are red. Contact lens may be reinserted 10 min following instillation.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decrease in ocular itching due to allergic conjunctivitis.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
There are no human eye data for bepotastine (Bepreve), ketotifen (Alaway), and olopatadine (Pataday, Patanol).
The company added that ISTAa[euro](tm)s four prescription products, Bromday, Bepreve, Istalol, and Vitrase, will complement its existing prescription ophthalmology products, including Lotemax and Besivance, and branded over the counter (OTC) eye vitamins PreserVision and Ocuvite.
Bepotastine (Bepreve; C), an antihistamine, and besifloxacin (Besivance; C), a quinolone antibiotic, are new ophthalmic products.